SMART101 after T-cell–depleted bone marrow transplant for blood cancers
Part of Blood & lymphatic, Cancer clinical trials.
This early-phase study tests SMART101 given after a T-cell–depleted (T-cell removed) donor bone marrow transplant. It aims to see if the treatment is safe and can help control certain high-risk blood cancers in children and adults.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have one of these blood cancers: acute leukemia (AML or ALL), or MDS, with high-risk features as defined by the study
- You are planning a T-cell–depleted donor stem cell transplant (allogeneic HSCT)
- You can receive the transplant based on general health and strength tests (Karnofsky/Lansky score at least 70)
- Your body organs must work normally enough before conditioning (the pre-transplant chemotherapy)
- Your donor must NOT be a matched sibling, matched cord blood (8/8), or a haploidentical donor
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental drug called CHT101 for blood cancers that have come back or stopped responding to other treatments. It targets a specific protein (CD70) on cancer cells, and the goal is to see if it can shrink or control the cancer.
This study tests a new drug, CHT101, given as an injection for people with certain blood cancers (like lymphoma or leukemia) that have returned or stopped responding to treatment. The goal is to see if CHT101 is safe, how it moves through the body, and if it can shrink the cancer.
This trial tests a specialized donor stem cell transplant to treat high-risk problems in the blood and bone marrow, including some cancers and non-cancers. It may help by using donor immune cells designed to better control the disease after transplant.
This study tests whether using cord blood stem cells (collected from umbilical cords after birth) can help treat high-risk blood cancers in children and young adults when a matched donor is not quickly available. Cord blood transplants may help prevent cancer from coming back.
This Phase 2 study tests a specialized stem cell transplant that removes certain immune “T-cell” receptors to help treat blood cancers like acute leukemia. It may help your body rebuild a healthier immune system after high-dose treatment.
This Phase 1 study tests a stem cell transplant plan that uses donor T-cells that have been specially processed and then added back. It aims to see if this approach is safer and works better for children and adults with serious blood cancers who need a transplant.
Hear when a new Hematological Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.